EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy



Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy



Urologic Clinics of North America 26(3): 465-479



Substantial and characteristic changes occur in the microscopic appearance and immunophenotype of the hyperplastic prostate and adenocarcinoma following androgen deprivation therapy and radiotherapy. These changes are rarely seen in untreated cancer, and in the authors' opinion, the combinations of features following therapy are sufficiently distinctive to warrant recognition. Pathologists must be aware of these distinct changes because of the reliance placed on nuclear and nucleolar size in the identification of prostate cancer, particularly in small specimens and lymph node metastases.

(PDF same-day service: $19.90)

Accession: 035980098

Download citation: RISBibTeXText

PMID: 10494285

DOI: 10.1016/S0094-0143(05)70195-6



Related references

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. Journal of Clinical Oncology 33(19): 2143-2150, 2015

DNA MemoChip: Long-Term and High Capacity Information Storage and Select Retrieval. Medical Science Monitor 24: 1185-1187, 2018

Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity. Acta Oncologica 44(6): 633-643, 2005

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scandinavian Journal of Urology and Nephrology 36(6): 405-413, 2003

Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. Journal of Urology 141(1): 68-72, 1989

Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?. Journal of Clinical Oncology 33(25): 2831-2832, 2015

Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58-9: Which patients need treatment intensification?. European Urology 69(4): E74-E75, 2016

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scandinavian Journal of Urology and Nephrology 42(3): 220-229, 2008

Words of wisdom. Re: Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. European Urology 55(2): 525-525, 2009

Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head & Neck 36(1): E4-E7, 2014

Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics 80(4): 1064-1071, 2011

Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. International Journal of Radiation Oncology, Biology, Physics 81(5): E721-E726, 2012

Effects of neoadjuvant androgen deprivation therapy on prostatic cancer. European Urology 30 Suppl 1: 26-31; Discussion 38-9, 1996

Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology 81(1): 130-134, 2013